Stress Management Program for Von Hippel-Lindau Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
The Relaxation Response Resiliency Program (3RP) has shown efficacy in improving coping and resilience across diverse populations; however, little is known about how it helps individuals manage the challenges of living with a chronic illness. This study proposes to pilot test an adapted version of the 3RP among patients living with VHL.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It seems focused on stress management, so it's likely you can continue your medications, but please confirm with the study team.
How does the 3RP-VHL treatment differ from other treatments for Von Hippel-Lindau Syndrome?
What evidence supports the effectiveness of the stress management treatment 3RP-VHL for Von Hippel-Lindau Syndrome?
Research on stress management in cancer patients shows that managing stress can improve psychological well-being and potentially lead to better health outcomes. This suggests that similar stress management programs might help people with Von Hippel-Lindau Syndrome by improving their quality of life and health.26789
Who Is on the Research Team?
Giselle Perez, PhD
Principal Investigator
Massachusetts General Hospital
Are You a Good Fit for This Trial?
This trial is for adults over 18 with a confirmed diagnosis of Von Hippel-Lindau (VHL) disease, which is a genetic disorder. Participants must be able to engage in videoconferencing sessions and not have any medical or psychiatric conditions that would prevent full participation as assessed by a physician.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Phase I - Descriptive
Conducting interviews with patients and caregivers to understand the challenges of living with VHL and patient's programmatic needs
Phase II - Treatment
Testing the adapted 3RP-VHL program in up to 40 patients with weekly sessions over approximately 8 weeks
Follow-up
Participants are monitored for feasibility and acceptability outcomes post-treatment
What Are the Treatments Tested in This Trial?
Interventions
- 3RP-VHL
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor
The Rappaport Foundation
Collaborator
The Claflin Distinguished Scholar Awards
Collaborator